167 related articles for article (PubMed ID: 35475682)
1. Contribution of Surface-Exposed Loops on the HPV16 Capsid to Antigenic Domains Recognized by Vaccine or Natural Infection Induced Neutralizing Antibodies.
Godi A; Vaghadia S; Cocuzza C; Miller E; Beddows S
Microbiol Spectr; 2022 Jun; 10(3):e0077922. PubMed ID: 35475682
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
[TBL] [Abstract][Full Text] [Related]
3. Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency.
Oumeslakht L; Ababou M; Badaoui B; Qmichou Z
Gene; 2021 May; 782():145533. PubMed ID: 33636291
[TBL] [Abstract][Full Text] [Related]
4. Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine.
Godi A; Bissett SL; Miller E; Beddows S
PLoS One; 2015; 10(10):e0140926. PubMed ID: 26495976
[TBL] [Abstract][Full Text] [Related]
5. Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines.
Ahmed AI; Bissett SL; Beddows S
Infect Genet Evol; 2013 Aug; 18():151-9. PubMed ID: 23722024
[TBL] [Abstract][Full Text] [Related]
6. Global evaluation of lineage-specific human papillomavirus capsid antigenicity using antibodies elicited by natural infection.
Kamuyu G; Coelho da Silva F; Tenet V; Schussler J; Godi A; Herrero R; Porras C; Mirabello L; Schiller JT; Sierra MS; Kreimer AR; Clifford GM; Beddows S
Nat Commun; 2024 Feb; 15(1):1608. PubMed ID: 38383518
[TBL] [Abstract][Full Text] [Related]
7. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X
Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766
[TBL] [Abstract][Full Text] [Related]
8. HPV16 L1 diversity and its potential impact on the vaccination-induced immunity.
El Aliani A; El Abid H; Kassal Y; Khyatti M; Attaleb M; Ennaji MM; El Mzibri M
Gene; 2020 Jul; 747():144682. PubMed ID: 32304786
[TBL] [Abstract][Full Text] [Related]
9. The DE and FG loops of the HPV major capsid protein contribute to the epitopes of vaccine-induced cross-neutralising antibodies.
Bissett SL; Godi A; Beddows S
Sci Rep; 2016 Dec; 6():39730. PubMed ID: 28004837
[TBL] [Abstract][Full Text] [Related]
10. Impact of naturally occurring variation in the human papillomavirus (HPV) 33 capsid proteins on recognition by vaccine-induced cross-neutralizing antibodies.
Godi A; Bissett SL; Miller E; Beddows S
J Gen Virol; 2017 Jul; 98(7):1755-1761. PubMed ID: 28691664
[TBL] [Abstract][Full Text] [Related]
11. The U4 Antibody Epitope on Human Papillomavirus 16 Identified by Cryo-electron Microscopy.
Guan J; Bywaters SM; Brendle SA; Lee H; Ashley RE; Christensen ND; Hafenstein S
J Virol; 2015 Dec; 89(23):12108-17. PubMed ID: 26401038
[TBL] [Abstract][Full Text] [Related]
12. Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.
Bissett SL; Draper E; Myers RE; Godi A; Beddows S
Vaccine; 2014 Feb; 32(10):1139-46. PubMed ID: 24440205
[TBL] [Abstract][Full Text] [Related]
13. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
Slupetzky K; Gambhira R; Culp TD; Shafti-Keramat S; Schellenbacher C; Christensen ND; Roden RB; Kirnbauer R
Vaccine; 2007 Mar; 25(11):2001-10. PubMed ID: 17239496
[TBL] [Abstract][Full Text] [Related]
14. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
Jagu S; Karanam B; Wang JW; Zayed H; Weghofer M; Brendle SA; Balogh KK; Tossi KP; Roden RBS; Christensen ND
Vaccine; 2015 Oct; 33(42):5553-5563. PubMed ID: 26382603
[TBL] [Abstract][Full Text] [Related]
15. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
[TBL] [Abstract][Full Text] [Related]
16. Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins.
Bissett SL; Mattiuzzo G; Draper E; Godi A; Wilkinson DE; Minor P; Page M; Beddows S
Vaccine; 2014 Nov; 32(48):6548-55. PubMed ID: 25203446
[TBL] [Abstract][Full Text] [Related]
17. Impact of naturally occurring variation in the human papillomavirus 52 capsid proteins on recognition by type-specific neutralising antibodies.
Godi A; Bissett SL; Masloh S; Fleury M; Li S; Zhao Q; Xia N; Cocuzza CE; Beddows S
J Gen Virol; 2019 Feb; 100(2):237-245. PubMed ID: 30657447
[TBL] [Abstract][Full Text] [Related]
18. Mutations on the FG surface loop of human papillomavirus type 16 major capsid protein affect recognition by both type-specific neutralizing antibodies and cross-reactive antibodies.
Carpentier GS; Fleury MJ; Touzé A; Sadeyen JR; Tourne S; Sizaret PY; Coursaget P
J Med Virol; 2005 Dec; 77(4):558-65. PubMed ID: 16254978
[TBL] [Abstract][Full Text] [Related]
19. Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera.
Carter JJ; Wipf GC; Madeleine MM; Schwartz SM; Koutsky LA; Galloway DA
J Virol; 2006 May; 80(10):4664-72. PubMed ID: 16641259
[TBL] [Abstract][Full Text] [Related]
20. A cryo-electron microscopy study identifies the complete H16.V5 epitope and reveals global conformational changes initiated by binding of the neutralizing antibody fragment.
Lee H; Brendle SA; Bywaters SM; Guan J; Ashley RE; Yoder JD; Makhov AM; Conway JF; Christensen ND; Hafenstein S
J Virol; 2015 Jan; 89(2):1428-38. PubMed ID: 25392224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
